Core Viewpoint - The company has established a dedicated settlement account for cash management of temporarily idle raised funds, ensuring compliance with regulations and enhancing the efficiency of fund utilization [2][3][4]. Group 1: Cash Management Plan - The company plans to use up to 170 million yuan from publicly issued convertible bonds and up to 1.7 billion yuan from non-publicly issued stock for cash management, focusing on safe and liquid financial products [2]. - The cash management will involve purchasing structured deposits, large certificates of deposit, treasury reverse repos, and other high-security, principal-protected products, with a holding period not exceeding 12 months [2][3]. Group 2: Account Establishment - A specialized settlement account for cash management has been opened at Zhengzhou Bank, specifically for the temporarily idle funds from the company's 2020 non-public stock issuance [3]. - The account will only be used for cash management of the raised funds and will not hold non-raised funds or serve other purposes [3]. Group 3: Risk Control Measures - The company will adhere to relevant regulations and guidelines in managing cash, including the Shanghai Stock Exchange rules and company bylaws [4]. - There will be a monitoring system in place to assess potential risks associated with investment products, with independent oversight from the board and audit committee [4]. Group 4: Impact on the Company - The cash management of idle funds will not affect the normal operation of fundraising projects or the company's main business, ensuring that shareholder interests are protected [4]. - This strategy is expected to improve the efficiency of fund utilization and increase returns on cash assets for the company and its shareholders [4].
郑州安图生物工程股份有限公司关于开立募集资金现金管理产品专用结算账户的公告